CCAAT-Enhancer-Binding Protein-beta

Subscribe to Selected New Research on CCAAT-Enhancer-Binding Protein-beta

299 relevant articles (2 outcomes, 26 trials/studies) found for this Bio-Agent

Description: A CCAAT-enhancer-binding protein found in LIVER; INTESTINES; LUNG and ADIPOSE TISSUE. It is an important mediator of INTERLEUKIN-6 signaling.

Also Known As:

23-C-EBP Protein; 40-C-EBP Protein; AGP-EBP Transcription Factor; C-EBP beta; C-EBP-Related Protein 2; C-EBPbeta; CRP2 Protein; IL-6 DBP; IL-6-Dependent DNA Binding Protein; Interleukin-6 Nuclear Factor; LAP Transcription Factor; Liver-Enriched Inhibiting Protein; Liver-Enriched Inhibitory Protein, LIP; 2, C-EBP-Related Protein; AGP EBP Transcription Factor; C EBP Related Protein 2; C EBP beta; C EBPbeta; CCAAT Enhancer Binding Protein beta; IL 6 Dependent DNA Binding Protein; Inhibiting Protein, Liver-Enriched; Interleukin 6 Nuclear Factor; Liver Enriched Inhibiting Protein; Liver Enriched Inhibitory Protein, LIP; Nuclear Factor, Interleukin-6; Protein-beta, CCAAT-Enhancer-Binding; Transcription Factor, AGP-EBP; Transcription Factor, LAP; C-EBP-beta; NF-IL6

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 56662

Transcription Factors: 9836

Basic-Leucine Zipper Transcription Factors: 13

CCAAT-Enhancer-Binding Proteins: 132

CCAAT-Enhancer-Binding Protein-beta: 299

Nuclear Proteins: 1291

CCAAT-Enhancer-Binding Proteins: 132

CCAAT-Enhancer-Binding Protein-beta: 299

DNA-Binding Proteins: 535

Basic-Leucine Zipper Transcription Factors: 13

CCAAT-Enhancer-Binding Proteins: 132

CCAAT-Enhancer-Binding Protein-beta: 299

Experts

1.	Buck, Martina: 2 articles (12/2007 - 01/2007)
2.	Chojkier, Mario: 2 articles (12/2007 - 01/2007)
3.	Kishimoto, Takashi: 2 articles (11/2007 - 06/2005)
4.	Johnson, Peter F: 2 articles (09/2006 - 04/2004)
5.	Fu, Bei Bei: 2 articles (10/2005 - 12/2003)
6.	Sun, Li: 2 articles (10/2005 - 12/2003)
7.	Liu, Ding Gan: 2 articles (10/2005 - 12/2003)
8.	Cortés-Canteli, Marta: 2 articles (04/2004 - 02/2002)
9.	Akagi, T: 1 article (09/2008)
10.	Gui, D: 1 article (09/2008)

Related Diseases

1.	Neoplasms (Cancer) 09/19/2008 - "Consistent with the positive role of HDAC1-C/EBPbeta complexes in liver proliferation, we have found that the CUGBP1-HDAC1-C/EBPbeta pathway is activated in human tumor liver samples, suggesting that HDAC1-C/EBPbeta complexes are involved in the development of liver tumors" 11/01/2007 - "CCAAT/enhancer binding protein-beta promotes the survival of intravascular rat pancreatic tumor cells via antiapoptotic effects." 08/01/2007 - "Overexpression of C/EBPbeta has been reported in several human tumors" 05/01/2006 - "Although C/EBPbeta has tumor suppressor-like activity in MEFs, other observations point to critical pro-oncogenic functions for C/EBPbeta in certain cancers" 03/01/2006 - "These data suggest that increased expression of C/EBP beta may contribute to the promotion of tumor invasiveness and progression" Order ALL the reference details at left...
2.	DNA Damage 11/01/2008 - "C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf)." 11/01/2008 - "These results indicate that C/EBPbeta represses p53 to promote cell survival downstream of DNA damage and suggest that inhibition of C/EBPbeta may be a target for cancer cotherapy to increase the efficacy of alkylating chemotherapeutic agents." 06/14/1996 - "In this report we have demonstrated that treatment of rat pheochromocytoma PC12 cells with sodium arsenite leads to enhanced expression of C/EBP-beta and GADD153 (growth arrest and DNA damage inducible gene 153) but not other C/EBPs" 02/15/2005 - "Expression of CCAAT/enhancer-binding protein beta (C/EBP beta) and growth-arrest DNA damage-inducible 153/C/EBP beta homology protein (GADD153/CHOP) increased after incubation of human neuroblastoma SH-SY5Y cells with a range of dopamine concentrations" Order ALL the reference details at left...
3.	Atherosclerosis (Atheroma) 03/16/2007 - "Our work uncovers a novel role for C/EBPbeta as a mediator of PPARdelta-dependent 14-3-3epsilon gene regulation in human endothelial cells and provides insight into the mechanism by which PPARdelta agonists may be beneficial in atherosclerosis." 09/14/2007 - "These results, confirmed in primary human hepatocytes and CASMC, demonstrate for the first time that IL-17 is a potent inducer of CRP expression via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation and suggest that IL-17 may mediate chronic inflammation, atherosclerosis, and thrombosis." Order ALL the reference details at left...
4.	Leukemia 12/01/1998 - "In order to identify the downstream genes of NF-IL6 in a monocytic lineage, we combined an inducible expression system with subtraction cloning in a study of murine M1 monocytic leukemia cells" 02/01/1997 - "This is significantly different from the apparent effects of NF-IL6 in leukemia cells and in fibroblasts" 11/03/2003 - "We further provide evidence that ATRA mediates a direct increase of C/EBPbeta, only in PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha)-expressing cells" 01/15/1992 - "This study showed that the expression of NF-IL6 messenger RNA (mRNA) increased markedly during the differentiation to a (mRNA) increased markedly during the differentiation to a macrophage lineage in mouse myeloid leukemia cells M1, human histiocytic leukemia cells U937, promyelocytic leukemia cells HL-60, and human peripheral monocytes" 07/01/2005 - "To investigate the roles of TFs in human B-cell precursors (BCPs), the present study analyzed the expression of the following 16 hematopoietic TFs: AML1, C/EBPalpha, C/EBPbeta, C/EBPgamma, C/EBPepsilon, E2A, Ets-1, GATA-1, GATA-2, GATA-3, Ikaros, IRF-1, Pax5, PU.1, T-bet and TCF-1 in 30 human BCP-leukemia cell lines" Order ALL the reference details at left...
5.	Infection 03/15/2008 - "C/EBPbeta-deficient mice develop normally; however, they exhibit defective macrophage function, resulting in increased susceptibility to infection" 10/15/2006 - "The electromobility shift assay showed that C/EBPbeta, a key transcriptional factor in response to pulmonary infections, binds to the "T" allele, but not to the "A" allele" 01/06/2004 - "Infection of 3T3-L1 preadipocytes with an adenovirus A-C/EBP expression vector interferes with C/EBPbeta function after induction of differentiation" 08/04/2003 - "These results suggest that CSF-induced and HIV-1-mediated distinct regulation of Hck and small isoform of C/EBPbeta represent the heterogeneous susceptibility of tissue MPhi to HIV-1 infection, and the regulation of Hck and C/EBPbeta are closely related and these two molecules affect one another." 08/04/2003 - "GM-MPhi express a high level of C/EBPbeta and a low level of Hck, and HIV-1 infection drastically increases the expression of a short isoform of C/EBPbeta but decreases that of Hck" Order ALL the reference details at left...

Related Drugs and Biologics

1.	PPAR delta
2.	Transcription Factors (Transcription Factor)
3.	CCAAT-Enhancer-Binding Protein-alpha
4.	NF-kappa B (NF-kB)
5.	CCAAT-Enhancer-Binding Protein-beta
6.	Interleukin-6 (Interleukin 6)
7.	CCAAT-Enhancer-Binding Proteins
8.	Protein Isoforms (Isoforms)
9.	Messenger RNA (mRNA)
10.	PPAR gamma

Related Therapies and Procedures

1.	Chemoprevention
2.	Pancreatectomy
3.	Moxibustion
4.	Induced Hyperthermia (Thermotherapy)
5.	Aftercare (After-Treatment)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18510 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>